Introduction. The development of hemophilic arthropathy causes degenerative joint damage that leads to functional impairment, limiting physical activity and causing disability in patients with hemophilia. Objectives. i) To assess the level of physical activity in patients with hemophilia; ii) To identify the best predictive model for physical activity in adult patients with hemophilic arthropathy. Material and method. Multicenter cross-sectional cohort study. Eighty-eight patients will be recruited. The dependent variable will be physical activity (International Physical Activity Questionnaire). Secondary variables will be kinesiophobia (Tampa Kinesiophobia Scale), functionality (Functional Independence Scale in Hemophilia), pain intensity, and clinical, anthropometric, and sociodemographic variables.
Study Type
OBSERVATIONAL
Enrollment
88
No intervention will be carried out in this study; the recruited patients will only complete the questionnaires provided below
Universidad Católica San Antonio de Murcia
Murcia, Spain
Measurement of physical activity level
Physical activity levels will be assessed using the International Physical Activity Questionnaire (IPAQ). This tool assesses physical activity levels in adults aged 18 to 65. It consists of seven questions that ask about the frequency, duration, and intensity of physical activity performed in the last week. It also assesses the time spent walking and sitting. The results are classified into three categories: low, moderate, and high activity. The unit of measurement is metabolic equivalent task (METS), where a higher number of METS indicates greater physical activity.
Time frame: Screening visit
Measurement of fear of movement
Fear of movement will be measured using the Tampa Kinesiophobia Scale (TSK). This self-reported questionnaire consists of 17 items, using a 4-point Likert scale. It comprises two subscales: avoidance of physical exertion due to fear of injury or pain, and belief that significant underlying medical problems exist. The total score ranges from 17 to 68 points, with a score of 37 or more indicating a high level of kinesiophobia
Time frame: Screening visit
Measurement of degree of functional independence
The degree of functional independence of patients will be measured using the Functional Independence Scale for Hemophilia (FISH). This tool measures eight activities of daily living: eating, personal hygiene, dressing, transferring from a chair, squatting, walking, climbing stairs, and running. Each activity is rated according to the level of assistance required, using a scale from 1 to 4. The total score can reach a maximum of 32 points, with a higher score indicating greater functional independence.
Time frame: Screening visit
Measurement of the joint pain
Pain intensity will be measured using the Visual Analog Scale (VAS). This is a simple and effective tool for measuring pain intensity. It consists of a horizontal line, usually 10 cm long, with one end representing "no pain" and the other "maximum pain imaginable."
Time frame: Screening visit
Measurement of age
The sociodemographic variable age will be measured in months completed from the date of birth
Time frame: Screening visit
Measurement of marital status
The sociodemographic variable marital status will be measured as a qualitative variable (single/married/divorced/widowed).
Time frame: Screening visit
Measurement of educational level
The sociodemographic variable educational level will be measured as a qualitative variable (primary education/secondary education/university education/vocational training).
Time frame: Screening visit
Measurement of employment status
The sociodemographic variable employment status will be measured as a qualitative variable (self-employed/employed by others/civil servant/unemployed/unable to work/retired).
Time frame: Screening visit
Measurement of hemophilia type
The clinical variable hemophilia type will be measured as a dichotomous variable (hemophilia A/hemophilia B).
Time frame: Screening visit
Measurement of type of drug treatment
The clinical variable drug treatment will be measured as a dichotomous variable (on-demand treatment/prophylactic treatment).
Time frame: Screening visit
Measurement of inhibitor development
The clinical variable development of antibodies prior to FVIII/FIX concentrates (inhibitors) will be measured as a dichotomous variable (yes/no).
Time frame: Screening visit
Measurement of weight
The anthropometric variable weight will be measured as a quantitative variable (measured in kg).
Time frame: Screening visit
Measurement of height
The anthropometric variable height will be measured as a quantitative variable (measured in cm).
Time frame: Screening visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.